Article Text
Statistics from Altmetric.com
Commentary on: Weston PJ, Harris DL, Battin M, et al. Oral dextrose gel for the treatment of hypoglycaemia in newborn infants. Cochrane Database Syst Rev 2016:CD011027.
Implications for practice and research
The effectiveness of oral dextrose gel in correcting neonatal hypoglycaemia and therefore in reducing long-term neurodevelopmental impairment, remains unclear.
Use of 40% oral dextrose gel for the treatment of neonatal hypoglycaemia improved maternal-infant bonding during the hospital stay and increased exclusive breast feeding after discharge.
More evidence about use of dextrose gel for the correction of neonatal hypoglycaemia and its impact on neurodevelopmental outcomes is required.
Context
Neonatal hypoglycaemia is a common problem and a preventable cause of neurological injury.1 Forty per cent oral dextrose gel is a novel therapy and is being increasingly used for the treatment of neonatal hypoglycaemia. A systemic review by Weston et al aimed to evaluate the available evidence on the effectiveness of dextrose gel in correcting hypoglycaemia and its impact on neurodevelopment outcomes.
Methods
A Cochrane systematic review …
Footnotes
Funding NIH (SL) - NICHD HD072929 and Dr Henry C and Bertha H Buswell Fellowship grant (PC).
Competing interests None declared.
Provenance and peer review Commissioned; internally peer reviewed.